The Experts below are selected from a list of 201 Experts worldwide ranked by ideXlab platform
Simon Francis Thomsen - One of the best experts on this subject based on the ideXlab platform.
-
Adalimumab for the treatment of refractory Acne Conglobata.
JAMA dermatology, 2013Co-Authors: Freja Lærke Sand, Simon Francis ThomsenAbstract:Tumor necrosis factor (TNF) inhibitors have become important components of the treatment of multiple chronic inflammatory disorders such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, Crohn disease, and ulcerative colitis. Furthermore, off-label use of TNF inhibitors has been reported for a variety of other diseases. We report a case of refractory Acne Conglobata treated with the TNF inhibitor adalimumab.
Anwar Qais Saadoon - One of the best experts on this subject based on the ideXlab platform.
-
Acne Conglobata of the Scalp.
International journal of trichology, 2020Co-Authors: Khalil I. Al-hamdi, Anwar Qais SaadoonAbstract:Acne Conglobata (AC) is a rare form of severe and chronic nodulocystic Acne. It is characterized by nodulocystic lesions, borrowing, interconnecting abscesses, scars, in addition to grouped comedones. AC usually appears on the trunk and may extend to the buttocks. It can also appear, to a lesser extent, on the face, neck, shoulders, proximal arms, abdomen, and thighs. To the best of our knowledge, AC of the scalp has not been reported in the literature. Herein, we are reporting a case of AC of the scalp, emphasizing its clinical and trichoscopic features and how to differentiate it clinically from similar scalp conditions, especially alopecic and aseptic nodules of the scalp and dissecting cellulitis of the scalp.
Freja Lærke Sand - One of the best experts on this subject based on the ideXlab platform.
-
Adalimumab for the treatment of refractory Acne Conglobata.
JAMA dermatology, 2013Co-Authors: Freja Lærke Sand, Simon Francis ThomsenAbstract:Tumor necrosis factor (TNF) inhibitors have become important components of the treatment of multiple chronic inflammatory disorders such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, Crohn disease, and ulcerative colitis. Furthermore, off-label use of TNF inhibitors has been reported for a variety of other diseases. We report a case of refractory Acne Conglobata treated with the TNF inhibitor adalimumab.
Xiuli Wang - One of the best experts on this subject based on the ideXlab platform.
-
Topical 5-aminolevulinic acid photodynamic therapy improved refractory Acne Conglobata and perifolliculitis capitis abscedens et suffodiens rather than hidradenitis suppurativa
Journal of Innovative Optical Health Sciences, 2016Co-Authors: Linglin Zhang, Peiru Wang, Lei Shi, Guolong Zhang, Yunfeng Zhang, Zhongxia Zhou, Zheng Huang, Hongwei Wang, Xiuli WangAbstract:Acne Conglobata (AC), perifolliculitis capitis abscedens et suffodiens (PCAS) and hidradenitis suppurativa (HS) are uncommon refractory chronic, inflammatory, scarring diseases but cause serious damage to the quality of life. These three diseases are associated with follicular occlusion. Several studies indicated topical 5-aminolevulinic acid photodynamic therapy (ALA-PDT) improved follicular occlusion besides Acne treatment. So we attempted to apply ALA-PDT to medicine resistant AC, PCAS and HS. Topical ALA-PDT was applied to 10 patients with AC, seven patients with PCAS and three patients with HS for more than three sessions. All the patients completed the dermatology life quality index (DLQI) questionnaire and were assessed for the efficacy at the baseline and on two weeks after each treatment. Adverse effects were recorded at each visit. The results showed 25.5% (5/20, two cases of AC and three cases of PCAS) of patients achieved excellent improvement after three sessions of PDT and another 60.0% (12/20, eight cases of AC and four cases of PCAS) of patients achieved good improvement. 15.0% (3/20, three cases of HS) got poor response ([Formula: see text] 20% lesions clearance). Another five cases (three cases of AC and two cases of PCAS) also achieved excellent response after 5–7 sessions of PDT. We also found that papular/nodular, cyst/abscess showed higher clearance rate than sinus/fistula (88.5%, 86.1% versus 11.1%). DLQI was reduced after three sessions of PDT in AC and PCAS patients rather than HS patients. 5-ALA-PDT could improve refractory AC and PCAS but could not lead to improvement in late stage of HS. The efficacy increased with more treatment sessions.
-
Topical 5-aminolevulinic acid photodynamic therapy improved refractory Acne Conglobata and perifolliculitis capitis abscedens et suffodiens rather than hidradenitis suppurativa
Journal of Innovative Optical Health Sciences, 2016Co-Authors: Linglin Zhang, Peiru Wang, Lei Shi, Guolong Zhang, Yunfeng Zhang, Zhongxia Zhou, Zheng Huang, Hongwei Wang, Xiuli WangAbstract:Acne Conglobata (AC), perifolliculitis capitis abscedens et suffodiens (PCAS) and hidradenitis suppurativa (HS) are uncommon refractory chronic, inflammatory, scarring diseases but cause serious damage to the quality of life. These three diseases are associated with follicular occlusion. Several studies indicated topical 5-aminolevulinic acid photodynamic therapy (ALA-PDT) improved follicular occlusion besides Acne treatment. So we attempted to apply ALA-PDT to medicine resistant AC, PCAS and HS. Topical ALA-PDT was applied to 10 patients with AC, seven patients with PCAS and three patients with HS for more than three sessions. All the patients completed the dermatology life quality index (DLQI) questionnaire and were assessed for the efficacy at the baseline and on two weeks after each treatment. Adverse effects were recorded at each visit. The results showed 25.5% (5/20, two cases of AC and three cases of PCAS) of patients achieved excellent improvement after three sessions of PDT and another 60.0% (12/20, eight cases of AC and four cases of PCAS) of patients achieved good improvement. 15.0% (3/20, three cases of HS) got poor response (< 20% lesions clearance). Another five cases (three cases of AC and two cases of PCAS) also achieved excellent response after 5–7 sessions of PDT. We also found that papular/nodular, cyst/abscess showed higher clearance rate than sinus/fistula (88.5%, 86.1% versus 11.1%). DLQI was reduced after three sessions of PDT in AC and PCAS patients rather than HS patients. 5-ALA-PDT could improve refractory AC and PCAS but could not lead to improvement in late stage of HS. The efficacy increased with more treatment sessions.
Muhammad A. Khan - One of the best experts on this subject based on the ideXlab platform.
-
Spondyloarthritis Associated with Acne Conglobata, Hidradenitis Suppurativa and Dissecting Cellulitis of the Scalp: A Review with Illustrative Cases
Current Rheumatology Reports, 2013Co-Authors: Neena M. James, Sobia Hassan, Muhammad A. KhanAbstract:To review and highlight the association of Acne Conglobata, hidradenitis suppurativa, and dissecting cellulitis of the scalp with inflammatory arthritic conditions, we report five illustrative patients with this association, and a review of the literature. All our patients were African-American males, and their skin disease present before the onset of arthritis. Both asymmetric peripheral arthritis and axial disease can occur. The arthritis is usually insidious and lacks association with rheumatoid factor and HLA-B27. Imaging of peripheral joints can reveal erosions, periosteal bone reaction and new bone formation. When the axial skeleton is involved, imaging can reveal sacroiliitis, syndesmophyte formation. NSAIDs, oral and intra-articular steroids, DMARDs and TNF alpha antagonists have all been used with success. Controlled trials with larger numbers of patients are needed to assess which treatment options are the most effective for this group of patients.
